Abstract: A medicament for treating or preventing pruritus is provided. For the medicament for treating or preventing pruritus, a compound having a blocking action on Cav3.2T-type calcium channels represented by General Formulas (I) to (VI), a tautomer of the compound, a stereoisomer of the compound, a pharmaceutically acceptable salt thereof, or a solvate thereof is used as an active ingredient.

Abstract: Described are methods and products related to the identification of multiple sclerosis (MS) as a transmissible protein misfolding disorder. Data is presented to support the position that the transmissible protein is an abnormal prion protein conformer (PrPMS). Methods are described for identifying a subject having, or at risk of developing, multiple sclerosis (MS) based on determining the presence or absence of PrPMS in a sample from the subject. The presence of the abnormal prion protein conformer in the sample is indicative of the subject having MS or an increased risk of developing MS. Also described are therapeutics methods for the treatment of MS as well as cell cultures, non-human animal models and biological samples thereof useful for the study of MS.

Abstract: The invention provides methods treating pain by inhibiting a Cav3.2 channel expression or function, including the use of contacting said channel in situ with an inhibitor of USP5 or an inhibitor of the interaction between Cav3.2 and USP5.

Abstract: The invention provides methods treating pain by inhibiting a Cav3.2 channel expression or function, including the use of contacting said channel in situ with an inhibitor of USP5 or an inhibitor of the interaction between Cav3.2 and USP5.

Abstract: Compounds of the formula wherein m is 0, 1 or 2; wherein when m is 0, Z is O, when m is 1, Z is N, and when m is 2, Z is C; Y is H, OH, NH2, or an organic moiety of 1-20C, optionally additionally containing 1-8 heteroatoms selected from the group consisting of N, P, O, S and halo; each l1 and l2 is independently 0-5; l3 is 0 or 1; each of R1, R2 and R3 is independently alkyl (1-6C), aryl (6-10C) or arylalkyl (7-16C) optionally containing 1-4 heteroatoms selected from the group consisting of halo, N, P, O, and S or each of R1 and R2 may independently be halo, COOR, CONR2, CF3, CN or NO2, wherein R is H or lower alkyl (1-4C) or alkyl (1-6C); n is 0 or 1; X is a linker; with the proviso that Y is not a tropolone, a coumarin, or an antioxidant containing an aromatic group and with the further proviso that if l3 is 0, and either l1 and l2 is 0 or 1 and if R1 and/or R2 represent F in the para position, Z cannot be C or N; and are useful to treat pain.

Abstract: Certain piperazine substituted compounds are described which are useful in altering calcium channel activity.

Abstract: Compounds of the formula and their salts, wherein Cy represents cyclohexyl; Y is CH?CH?, CH?2, ? or Cy, X is trivalent straight-chain alkylene (3–10C) or trivalent straight-chain 1-alkenylene (3–10C) optionally substituted by oxo at the C adjacent N when n is 0 and Y is ?2CH; and is otherwise trivalent straight-chain alkylene (5–10C) or trivalent straight-chain 1-alkenylene (5–10C) optionally substituted by oxo at the C adjacent N; Z is N, NCO, CHNCOR1 or CHNR1, wherein R1 is alkyl (1–6C); and n is 0–5; wherein each ? and Cy independently may optionally be substituted by alkyl (1–6C) or by halo, CF3, OCF3, NO2, NR2, OR, SR, COR, COOR, CONR2, NROCR or OOCR where R is H or alkyl (1–4C), or two substituents may form a 5–7 membered ring with the proviso that the compounds of formula (1) contain at least one aromatic moiety, are useful as calcium channel blockers.

Abstract: Certain piperazine substituted compounds are described which are useful in altering calcium channel activity.

Abstract: Certain piperazine substituted compounds are described which are useful in altering calcium channel activity.

Abstract: Certain piperazine substituted compounds are described which are useful in altering calcium channel activity.

Abstract: Certain piperazine substituted compounds are described which are useful in altering calcium channel activity.

Abstract: Certain piperazine substituted compounds are described which are useful in altering calcium channel activity.

Abstract: Certain piperazine substituted compounds are described which are useful in altering calcium channel activity.

Abstract: Compounds of the formula 1

Abstract: Certain piperazine substituted compounds are described which are useful in altering calcium channel activity.

Abstract: Certain piperazine substituted compounds are described which are useful in altering calcium channel activity.

Abstract: Certain piperazine substituted compounds are described which are useful in altering calcium channel activity.

Abstract: Compounds comprising a straight backbone carbon chain of 8-16C, optionally substituted with 1-5 alkyl groups (1-6C); said chain optionally functionalized at one terminus with halo, —OR, —SR, —NR2, —OOCR, —NROCR wherein R is alkyl (1-6C), or phosphate or pyrophosphate, or functionalized wherein a terminal carbon is optionally in the form of —COOR, —CONR2 or —COR wherein R is alkyl (1-6C); and wherein said chain may optionally contain 1-&pgr;-bonds or the epoxides thereof are useful as calcium channel inhibitors. Libraries of these compounds can also be used to identify antagonists for other targets.